As proof of concept from a pharmaceutical perspective, drugs that (1) interfere with the TLR4/IKK/NF-kB axis, (2) target PPAR-γ, or (3) target pro-inflammatory cytokines, have demonstrated promise with respect to treating IR despite obesity. This evidence concerns the gene NFKB1 and obesity due to melanocortin 4 receptor deficiency.